A Phase 3 interventional study of Rozanolixizumab in Generalized Myasthenia Gravis, sponsored by UCB Biopharma SRL. Completed at 43 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing rozanolixizumab in Myasthenia Gravis — 2 open to participants now, 4 under way, 3 of them phase 3. rozanolixizumab · Myasthenia Gravis.
Among the 10 studies testing rozanolixizumab in Myasthenia Gravis, this one is the 5th largest by enrollment, is one of 2 that started in 2019, is one of 7 in phase 3, and was the 3rd registered.
331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.
Browse Myasthenia Gravis studies →2 of the 10 studies testing rozanolixizumab in Myasthenia Gravis are open now, in 9 countries. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United States, China, France and 4 more countries
Ages 18+
UCB Biopharma SRL · Sites in United States, Canada, China and 6 more countries
Ages 18+
By country, each count listing its studies:
rozanolixizumab: first FDA approval 2023 (RYSTIGGO), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 8 · Phase 4 1
First in 2017; this study’s year is marked. 2 started in 2019.
This study's enrollment of 71 is above the median of 44 across 218 interventional studies indexed under Myasthenia Gravis.
Median enrollment 67 across the 10 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 2 most frequent:
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
18 studies in Myasthenia Gravis by UCB S.A.: 5 open now, 7 under way, 5 of them phase 3. Of 11 finished, 9 (82%) have results posted.
Among the 18 studies in Myasthenia Gravis by UCB S.A., this one is the 7th largest by enrollment, is one of 4 that started in 2019, is one of 12 in phase 3, and was the 6th registered.
UCB S.A.’s Myasthenia Gravis studies by the year they started, since 2017.
2 of the studies testing rozanolixizumab in Myasthenia Gravis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06540144Phase 3UCB Biopharma SRLAn Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis | 2027-10-05 |
| NCT07246564UCB Biopharma SRLPhase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis | 2027-10-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing rozanolixizumab in Myasthenia Gravis, from their registry updates:
Among UCB S.A.’s 18 in Myasthenia Gravis:
This tab as a report to print or save as PDF → With an account.
The purpose of the MycarinGstudy is to evaluate the long-term safety, tolerability and long-term efficacy of rozanolixizumab in study participants with generalized myasthenia gravis (MG).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study participants randomized to dosage regimen 1 will receive assigned dosage of rozanolixizumab at pre-specified time points during the Treatment Period. The dose regimen may be switched based on investigator discretion.
Drug: Rozanolixizumab
Study participants randomized to dosage regimen 2 will receive assigned dosage of rozanolixizumab at pre-specified time points during the Treatment Period. The dose regimen may be switched based on investigator discretion.
Drug: Rozanolixizumab
Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
Also known as: UCB7665
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
A TEAE is defined as an AE starting on or after the time of first administration of investigational medicinal product (IMP) or any unresolved event already present before the first administration of IMP that worsened in intensity following exposure to IMP, up to 8 weeks after the last dose of IMP in study participants who discontinued the study or IMP.
Time frame: From Baseline until End of Study (up to Week 60)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Permanent Withdrawal of Study Medication
A TEAE is defined as an AE starting on or after the time of first administration of IMP or any unresolved event already present before the first administration of IMP that worsened in intensity following exposure to IMP, up to 8 weeks after the last dose of IMP in study participants who discontinued the study or IMP.
Time frame: From Baseline until End of Study (up to Week 60)
Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Each Scheduled Assessment During Treatment and Observation Periods
The Myasthenia Gravis Activities of Daily Living (MG-ADL) is an 8-item patient-reported outcome (PRO) instrument developed on the basis of the Quantitative Myasthenia Gravis (QMG). The MG-ADL targeted symptoms and disability across ocular, bulbar, respiratory, and axial symptoms. The total MG-ADL score was obtained by summing the responses to each individual item (8 items; Grades: 0, 1, 2, 3), where 0 represents no symptoms or impaired performance and 3 represents the most severe symptoms or impaired performance. The total score ranges from 0 to 24, with a higher score indicating more disability. A positive change indicates worsening and a negative change indicates improvement.
Time frame: Baseline, Weeks 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 52 and 60
Change From Baseline in Myasthenia Gravis-Composite (MG-C) Total Score at Each Scheduled Assessment During Treatment and Observation Periods
MG-C scale is a validated assessment and scale tests 10 items with individual items being weighted differently. The items included ptosis/upward gaze (range: 0 \[\>45 second\] - 3 \[Immediate\]), double vision on lateral gaze (range: 0 \[\>45 second\] - 4 \[Immediate\]), eye closure (range: 0 \[Normal\] - 2 \[severe weakness\]), talking (range: 0 \[Normal\] - 6 \[difficult to understand speech\]), chewing (range: 0 \[Normal\] - 6 \[gastric tube\]), swallowing (range: 0 \[Normal\] - 6 \[gastric tube\]), breathing (range: 0 \[Normal\] - 9 \[ventilator dependence\]), neck flexion (range: 0 \[Normal\] - 4 \[severe weakness\]), shoulder abduction (range: 0 \[Normal\] - 5 \[severe weakness\]) and hip flexion (range: 0 \[Normal\] - 5 \[severe weakness\]), lower scores= lower disease activity. Total MG-C score was obtained by summing responses to each individual item and score ranges from 0 to 50, with lower scores indicating lower disease activity. A positive change indicates worsening and a negative change indicates improvement.
Time frame: Baseline, Weeks 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 52 and 60
Change From Baseline in Quantitative Myasthenia Gravis (QMG) Total Score at Each Scheduled Assessment During Treatment and Observation Periods
The QMG is a validated assessment and the scale tested 13 items, including ocular and facial involvement, swallowing, speech, limb strength, and forced vital capacity. The total QMG score was obtained by summing the responses to each individual item (13 items; Responses: None=0, Mild=1, Moderate=2, Severe=3) and the score ranges from 0 to 39, with lower scores indicating lower disease activity. A positive change indicates worsening and a negative change indicates improvement.
Time frame: Baseline, Weeks 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 52 and 60
Percentage of Participants Using Rescue Medication (Intravenous Infusion of Immunoglobulin G (IVIg) or Plasma Exchange (PEX))
Rescue therapy consisted of IVIg or PEX. Study participants who experienced disease worsening (eg, an increase of 2 points on the MG-ADL or 3 points on the QMG scale between 2 consecutive visits) may be considered for rescue therapy at the discretion of the Investigator.
Time frame: From Baseline until End of Study (up to Week 60)
The study started to enroll study participants in Oct 2019 and concluded in Sep 2021.
| Milestone | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg |
|---|---|---|
| Started | 35 | 36 |
| Safety set | 35 | 35 |
| Completed | 5 | 3 |
| Not completed | 30 | 33 |
| Withdrew: Adverse event, non-fatal | 3 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Rolled over to mg0007 study | 25 | 28 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Sponsor and participant decision | 0 | 1 |
| Withdrew: Personal surgery | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 |
A TEAE is defined as an AE starting on or after the time of first administration of investigational medicinal product (IMP) or any unresolved event already present before the first administration of IMP that worsened in intensity following exposure to IMP, up to 8 weeks after the last dose of IMP in study participants who discontinued the study or IMP.
| percentage of participants | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg |
|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | 76.0 | 78.6 |
A TEAE is defined as an AE starting on or after the time of first administration of IMP or any unresolved event already present before the first administration of IMP that worsened in intensity following exposure to IMP, up to 8 weeks after the last dose of IMP in study participants who discontinued the study or IMP.
| percentage of participants | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg |
|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Permanent Withdrawal of Study Medication | 6.0 | 0 |
The Myasthenia Gravis Activities of Daily Living (MG-ADL) is an 8-item patient-reported outcome (PRO) instrument developed on the basis of the Quantitative Myasthenia Gravis (QMG). The MG-ADL targeted symptoms and disability across ocular, bulbar, respiratory, and axial symptoms. The total MG-ADL score was obtained by summing the responses to each individual item (8 items; Grades: 0, 1, 2, 3), where 0 represents no symptoms or impaired performance and 3 represents the most severe symptoms or impaired performance. The total score ranges from 0 to 24, with a higher score indicating more disability. A positive change indicates worsening and a negative change indicates improvement.
| units on a scale | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg |
|---|---|---|
| Week 5 | -2.7 ± 3.3 | -3.2 ± 3.8 |
| Week 7 | -2.7 ± 3.8 | -3.7 ± 3.4 |
| Week 9 | -2.8 ± 3.4 | -3.4 ± 3.7 |
| Week 13 | -3.1 ± 3.4 | -3.9 ± 4.0 |
| Week 17 | -2.8 ± 3.3 | -4.0 ± 3.9 |
| Week 21 | -3.0 ± 3.4 | -4.1 ± 4.3 |
| Week 25 | -2.7 ± 3.0 | -3.7 ± 4.7 |
| Week 29 | -2.8 ± 2.1 | -3.6 ± 4.3 |
| Week 33 | -3.0 ± 2.8 | -3.5 ± 4.5 |
| Week 37 | -3.9 ± 2.5 | -3.6 ± 3.6 |
| Week 41 | -2.8 ± 2.1 | -1.8 ± 1.0 |
| Week 45 | -3.8 ± 2.4 | -2.1 ± 1.1 |
| Week 49 | -2.4 ± 1.1 | -0.5 ± 3.7 |
| Week 52 | -2.6 ± 1.3 | -2.0 ± NA |
| Week 60 | -0.3 ± 2.1 | -1.3 ± 3.9 |
MG-C scale is a validated assessment and scale tests 10 items with individual items being weighted differently. The items included ptosis/upward gaze (range: 0 \[\>45 second\] - 3 \[Immediate\]), double vision on lateral gaze (range: 0 \[\>45 second\] - 4 \[Immediate\]), eye closure (range: 0 \[Normal\] - 2 \[severe weakness\]), talking (range: 0 \[Normal\] - 6 \[difficult to understand speech\]), chewing (range: 0 \[Normal\] - 6 \[gastric tube\]), swallowing (range: 0 \[Normal\] - 6 \[gastric tube\]), breathing (range: 0 \[Normal\] - 9 \[ventilator dependence\]), neck flexion (range: 0 \[Normal\] - 4 \[severe weakness\]), shoulder abduction (range: 0 \[Normal\] - 5 \[severe weakness\]) and hip flexion (range: 0 \[Normal\] - 5 \[severe weakness\]), lower scores= lower disease activity. Total MG-C score was obtained by summing responses to each individual item and score ranges from 0 to 50, with lower scores indicating lower disease activity. A positive change indicates worsening and a negative change indicates improvement.
| units on a scale | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg |
|---|---|---|
| Week 5 | -4.7 ± 5.5 | -5.5 ± 7.3 |
| Week 7 | -5.0 ± 5.7 | -7.1 ± 7.4 |
| Week 9 | -5.0 ± 5.3 | -6.0 ± 7.4 |
| Week 13 | -4.8 ± 5.5 | -7.0 ± 7.8 |
| Week 17 | -4.4 ± 5.7 | -5.5 ± 8.6 |
| Week 21 | -5.3 ± 6.9 | -7.3 ± 8.1 |
| Week 25 | -6.1 ± 5.8 | -8.8 ± 7.7 |
| Week 29 | -5.1 ± 5.5 | -9.1 ± 9.2 |
| Week 33 | -4.6 ± 5.1 | -8.4 ± 8.6 |
| Week 37 | -6.3 ± 6.8 | -8.6 ± 6.9 |
| Week 41 | -6.0 ± 7.1 | -6.5 ± 5.8 |
| Week 45 | -4.0 ± 6.2 | -5.3 ± 4.9 |
| Week 49 | -1.4 ± 3.8 | -0.8 ± 9.2 |
| Week 52 | -3.8 ± 3.1 | NA ± NA |
| Week 60 | 1.7 ± 3.7 | -2.3 ± 8.5 |
The QMG is a validated assessment and the scale tested 13 items, including ocular and facial involvement, swallowing, speech, limb strength, and forced vital capacity. The total QMG score was obtained by summing the responses to each individual item (13 items; Responses: None=0, Mild=1, Moderate=2, Severe=3) and the score ranges from 0 to 39, with lower scores indicating lower disease activity. A positive change indicates worsening and a negative change indicates improvement.
| units on a scale | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg |
|---|---|---|
| Week 5 | -2.9 ± 4.7 | -4.5 ± 4.4 |
| Week 7 | -3.3 ± 4.4 | -5.2 ± 4.3 |
| Week 9 | -3.3 ± 3.8 | -4.7 ± 4.3 |
| Week 13 | -2.6 ± 4.2 | -5.5 ± 4.4 |
| Week 17 | -3.1 ± 4.9 | -4.2 ± 4.4 |
| Week 21 | -4.0 ± 4.7 | -5.1 ± 4.9 |
| Week 25 | -5.1 ± 4.6 | -5.7 ± 5.5 |
| Week 29 | -5.4 ± 3.6 | -5.5 ± 6.3 |
| Week 33 | -4.9 ± 4.8 | -6.2 ± 5.7 |
| Week 37 | -5.3 ± 3.9 | -6.8 ± 5.9 |
| Week 41 | -5.7 ± 4.3 | -4.0 ± 3.1 |
| Week 45 | -5.3 ± 2.8 | -4.0 ± 3.5 |
| Week 49 | -3.8 ± 0.8 | -1.8 ± 1.8 |
| Week 52 | -4.6 ± 2.9 | NA ± NA |
| Week 60 | -0.9 ± 2.4 | -1.8 ± 5.1 |
Rescue therapy consisted of IVIg or PEX. Study participants who experienced disease worsening (eg, an increase of 2 points on the MG-ADL or 3 points on the QMG scale between 2 consecutive visits) may be considered for rescue therapy at the discretion of the Investigator.
| percentage of participants | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg |
|---|---|---|
| Percentage of Participants Using Rescue Medication (Intravenous Infusion of Immunoglobulin G (IVIg) or Plasma Exchange (PEX)) | 11.4 | 0 |
Collected over From Baseline until End of Study (up to Week 60). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rozanolixizumab ~7 mg/kg | 0/50 (0%) | 7/50 (14%) | 27/50 (54%) |
| Rozanolixizumab ~10 mg/kg | 0/42 (0%) | 2/42 (4.8%) | 25/42 (59.5%) |
| Event | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg |
|---|---|---|
| Myasthenia gravisNervous system disorders | 3/50 | 1/42 |
| PericarditisCardiac disorders | 0/50 | 1/42 |
| Cardiac failure congestiveCardiac disorders | 1/50 | 0/42 |
| Retinal detachmentEye disorders | 1/50 | 0/42 |
| Biopsy kidney abnormalInvestigations | 1/50 | 0/42 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 1/50 | 0/42 |
| Event | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg |
|---|---|---|
| HeadacheNervous system disorders | 15/50 | 12/42 |
| DiarrhoeaGastrointestinal disorders | 6/50 | 7/42 |
| Blood immunoglobulin G decreasedInvestigations | 6/50 | 5/42 |
| NauseaGastrointestinal disorders | 4/50 | 5/42 |
| Urinary tract infectionInfections and infestations | 5/50 | 2/42 |
| VomitingGastrointestinal disorders | 0/50 | 4/42 |
| NasopharyngitisInfections and infestations | 2/50 | 4/42 |
| RashSkin and subcutaneous tissue disorders | 1/50 | 4/42 |
| PyrexiaGeneral disorders | 4/50 | 3/42 |
| Back painMusculoskeletal and connective tissue disorders | 2/50 | 3/42 |
Baseline Characteristics refer to the Randomized Set (RS) which consisted of all study participants who were randomized, using the treatment assigned instead of the actual treatment received.
| Age, Categorical(Participants) | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 29 | 26 | 55 |
| >=65 years | 6 | 10 | 16 |
| Age, Continuous(years) | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg | Total |
|---|---|---|---|
| Mean | 50.6 ± 14.2 | 53.7 ± 17.2 | 52.2 ± 15.8 |
| Sex: Female, Male(Participants) | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg | Total |
|---|---|---|---|
| Female | 19 | 19 | 38 |
| Male | 16 | 17 | 33 |
| Race/Ethnicity, Customized(Participants) | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg | Total |
|---|---|---|---|
| Asian | 4 | 4 | 8 |
| Black | 2 | 3 | 5 |
| White | 17 | 19 | 36 |
| Missing | 12 | 10 | 22 |
| Race/Ethnicity, Customized(Participants) | Rozanolixizumab ~7 mg/kg | Rozanolixizumab ~10 mg/kg | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 2 | 6 |
| Not Hispanic or Latino | 19 | 25 | 44 |
| Missing | 12 | 9 | 21 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Data sharing details ↗ · www.vivli.org
Ran from Oct 2019 to primary completion in Sep 2021, 22 months.
Results were first posted in Aug 2023, 1 year 11 months after primary completion. A results delay was requested in Aug 2022.
Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 22 months is below that.
Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rozanolixizumab